

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ADS/

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/803,653
				<b>Filing Date</b>	March 18, 2004
				<b>First Named Inventor</b>	John McCafferty, et al.
				<b>Group Art Unit</b>	1639
				<b>Examiner Name</b>	Amber D. Steele
<b>Sheet</b>	1	<b>of</b>	16	<b>Attorney Docket Number</b>	05569.0004.DVUS12

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number – Kind Code <sup>2</sup> (if known)			
	A1	4,704,692	11/03/1987	Ladner	
	A2	5,258,289	11/02/1993	Davis, et al.	
	A3	5,260,203	11/09/1993	Ladner, et al.	
	A4	5,567,610	10/22/1996	Borrebaeck, et al.	
	A5	5,580,717	12/03/1996	Dower, et al.	
	A6	5,698,426	12/16/1997	Huse	
	A7	5,780,225	07/14/1998	Wigler, et al.	
	A8	5,814,476	09/29/1998	Kauffman, et al.	
	A9	5,837,500	11/17/1998	Ladner, et al.	
	A10	5,840,479	11/24/1998	Little, et al.	
	A11	5,855,885	01/05/1999	Smith, et al.	
	A12	5,935,823	08/10/1999	Fowlkes, et al.	
	A13	5,948,635	09/07/1999	Kay, et al.	
	A14	5,955,358	09/21/1999	Huse	
	A15	6,225,447	05/01/2001	Winter, et al.	
	A16	6,291,650	09/18/2001	Winter, et al.	
	A17	7,195,866	03/27/2007	Griffiths, et al.	

U.S. PUBLICATION DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number – Kind Code <sup>2</sup> (if known)			

<b>Examiner Signature</b>	/Amber D. Steele/	<b>Date Considered</b>	09/04/2009
-------------------------------	-------------------	----------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds codes of USPTO Patent Documents as [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/803,653
				<b>Filing Date</b>	March 18, 2004
				<b>First Named Inventor</b>	John McCafferty, et al.
				<b>Group Art Unit</b>	1639
				<b>Examiner Name</b>	Amber D. Steele
Sheet	2	of	16	<b>Attorney Docket Number</b>	05569.0004.DVUS12

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T276
		Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	B1	EP 436597 B1	04/02/1997	Protein Engineering Corporation		
	B2	GB B-0349578 B1	01/10/1990	Enzon Labs Inc.		
	B3	EP 0324162	12/24/1988	Dr. Andreas Pluckthun		
	B4	GB 91/25579.4	02/12/1991	Cambridge Antibody Technology Ltd.		
	B5	GB 91/25582.8	02/12/1991	Cambridge Antibody Technology Ltd.		
	B6	WO 92-01047	01/23/1992	Cambridge Antibody Technology Ltd.		
	B7	WO 92-18619	10/29/1992	The Scripps Research Institute		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T <sup>2</sup>
	C1	U.S. Applc. No. 08/484,893 Advisory Action dated November 3, 1997	
	C2	U.S. Applc. No. 08/484,893 Final office action dated March 28, 1997	
	C3	U.S. Applc. No. 08/484,893 Non-final office action dated July 20, 1999	
	C4	U.S. Applc. No. 08/484,893 Non-Final office action dated June 17, 1996	
	C5	U.S. Applc. No. 08/484,893 Non-final office action dated June 9, 1998	
	C6	U.S. Applc. No. 08/484,893 Notice of Allowance dated March 29, 2000	
	C7	U.S. Applc. No. 08/484,893 Restriction Requirement dated December 7, 1998	
	C8	U.S. Applc. No. 09/196,522 Examiner's Amendment dated January 28, 2004	
	C9	U.S. Applc. No. 09/196,522 Restriction Requirement dated November 27, 1999	
	C10	U.S. Applc. No. 09/196,522 Non-final office action dated April 20, 2000	
	C11	U.S. Applc. No. 09/196,522 Non-final office action dated January 3, 2001	
	C12	U.S. Applc. No. 09/196,522 Notice of Allowance dated May 3, 2004	

<b>Examiner Signature</b>	/Amber D. Steele/	<b>Date Considered</b>	09/04/2009
-------------------------------	-------------------	----------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/803,653
				<b>Filing Date</b>	March 18, 2004
				<b>First Named Inventor</b>	John McCafferty, et al.
				<b>Group Art Unit</b>	1639
				<b>Examiner Name</b>	Amber D. Steele
Sheet	3	of	16	<b>Attorney Docket Number</b>	05569.0004.DVUS12

	C13	U.S. Appl. No. 09/196,586 Advisory Action dated December 5, 2008	
	C14	U.S. Appl. No. 09/196,586 Advisory Action dated May 4, 2007	
	C15	U.S. Appl. No. 09/196,586 Final office action dated September 22, 2006	
	C16	U.S. Appl. No. 09/196,586 Final office action dated April 17, 2001	
	C17	U.S. Appl. No. 09/196,586 Final office action dated December 22, 2004	
	C18	U.S. Appl. No. 09/196,586 Final office action dated September 15, 2008	
	C19	U.S. Appl. No. 09/196,586 Non final office action dated April 10, 2000	
	C20	U.S. Appl. No. 09/196,586 Non-final office action dated April 4, 2002	
	C21	U.S. Appl. No. 09/196,586 Non-final office action dated December 28, 2005	
	C22	U.S. Appl. No. 09/196,586 Non-Final office action dated January 9, 2008	
	C23	U.S. Appl. No. 09/196,586 Non-final office action dated May 19, 2004	
	C24	U.S. Appl. No. 09/196,586 Restriction Requirement dated December 21, 1999	
	C25	U.S. Appl. No. 09/196,673 Advisory Action dated November 6, 2002	
	C26	U.S. Appl. No. 09/196,673 Advisory Action dated March 24, 2003	
	C27	U.S. Appl. No. 09/196,673 Final office action dated December 22, 2004	
	C28	U.S. Appl. No. 09/196,673 Final office action dated May 14, 2002	
	C29	U.S. Appl. No. 09/196,673 Non-final office action dated April 11, 2000	
	C30	U.S. Appl. No. 09/196,673 Non-final office action dated January 18, 2001	
	C31	U.S. Appl. No. 09/196,673 Non-final office action dated March 4, 2004	
	C32	U.S. Appl. No. 09/196,673 Notice of Allowance dated November 3, 2005	
	C33	U.S. Appl. No. 09/196,673 Restriction Requirement dated December 21, 1999	
	C34	U.S. Appl. No. 09/309,639 Non-final office action dated January 3, 2001	
	C35	U.S. Appl. No. 09/309,639 Official communication dated August 22, 2003	
	C36	U.S. Appl. No. 09/309,639 Restriction Requirement dated September 1, 2000	
	C37	U.S. Appl. No. 09/416,902 Advisory Action dated September 6, 2006	
	C38	U.S. Appl. No. 09/416,902 Final office action dated March 10, 2006	
	C39	U.S. Appl. No. 09/416,902 Non-final office action dated July 28, 2005	
	C40	U.S. Appl. No. 09/416,902 Non-final office action dated August 16, 2007	
	C41	U.S. Appl. No. 09/416,902 Non-final office action dated February 3, 2009	
	C42	U.S. Appl. No. 09/416,902 Non-final office action dated September 19, 2008	
	C43	U.S. Appl. No. 09/416,902 Notice of Allowance dated February 4, 2008	
	C44	U.S. Appl. No. 09/416,902 Restriction Requirement dated September 18, 2000	
	C45	U.S. Appl. No. 09/417,478 Advisory Action dated January 29, 2007	
	C46	U.S. Appl. No. 09/417,478 Final office action dated April 1, 2009	
	C47	U.S. Appl. No. 09/417,478 Final office action dated December 14, 2007	
	C48	U.S. Appl. No. 09/417,478 Final office action dated July 5, 2006	
	C49	U.S. Appl. No. 09/417,478 Non-final office action dated January 20, 2000	

<b>Examiner Signature</b>	/Amber D. Steele/	<b>Date Considered</b>	09/04/2009
---------------------------	-------------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/803,653
				<b>Filing Date</b>	March 18, 2004
				<b>First Named Inventor</b>	John McCafferty, et al.
				<b>Group Art Unit</b>	1639
				<b>Examiner Name</b>	Amber D. Steele
Sheet	4	of	16	<b>Attorney Docket Number</b>	05569.0004.DVUS12

	C50	U.S. Appl. No. 09/417,478 Non-final office action dated June 12, 2008	
	C51	U.S. Appl. No. 09/417,478 Non-final office action dated May 17, 2007	
	C52	U.S. Appl. No. 09/417,478 Non-final office action dated November 20, 2000	
	C53	U.S. Appl. No. 09/417,479 Non-final office action dated May 3, 2006	
	C54	U.S. Appl. No. 09/417,479 Restriction Requirement dated June 26, 2000	
	C55	U.S. Appl. No. 09/706,507 Non-final office action dated May 5, 2006	
	C56	U.S. Appl. No. 09/706,507 Restriction Requirement dated May 21, 2001	
	C57	U.S. Appl. No. 09/726,219 Non-final office action dated August 12, 2003	
	C58	U.S. Appl. No. 09/726,219 Notice of Allowance dated February 25, 2004	
	C59	U.S. Appl. No. 09/726,219 Restriction Requirement dated March 12, 2003	
	C60	U.S. Appl. No. 07/971,857 Advisory Action dated August 15, 1996	
	C61	U.S. Appl. No. 07/971,857 Examiner's Interview Summary Record dated December 13, 1996	
	C62	U.S. Appl. No. 07/971,857 Examiner's Interview summary Record dated April 24, 1997	
	C63	U.S. Appl. No. 07/971,857 Final office action dated April 23, 1996	
	C64	U.S. Appl. No. 07/971,857 Non-final office action dated June 30, 1995	
	C65	U.S. Appl. No. 07/971,857 Notice of Allowance dated July 23, 1997	
	C66	U.S. Appl. No. 07/971,857 Response to 312 Amendment dated April 20, 1999	
	C67	U.S. Appl. No. 10/803,622 Examiner's Interview Summary dated March 20, 2008	
	C68	U.S. Appl. No. 10/803,622 Advisory Action dated July 31, 2007	
	C69	U.S. Appl. No. 10/803,622 Final office action dated April 10, 2007	
	C70	U.S. Appl. No. 10/803,622 Final office action dated February 17, 2009	
	C71	U.S. Appl. No. 10/803,622 Non-final office action dated July 3, 2008	
	C72	U.S. Appl. No. 10/803,622 Non-final office action dated July 5, 2006	
	C73	U.S. Appl. No. 10/803,622 Non-final office action dated October 2, 2007	
	C74	U.S. Appl. No. 10/803,622 Restriction Requirement dated April 10, 2006	
	C75	U.S. Appl. No. 11/555,464 Non-final office action dated March 5, 2009	
	C76	U.S. Appl. No. 11/555,519 Non-final office action dated March 5, 2009	
	C77	<b>Abbas, et al.</b> , "Cellular and Molecular Immunology," Saunders, Third Edition, p. 412 (1997)	
	C78	<b>Alberts, et al.</b> , "Molecular Biology of the Cell," Garland Publications, Third Edition, p. 96 (1994)	
	C79	<b>Avrameas and Ternynck</b> , "Natural Antibodies," in Delves, P., and I. Roitt, The Encyclopedia of Immunology, Second Edition, Academic Press, pp. 1806-1809 (1998)	

<b>Examiner Signature</b>	/Amber D. Steele/	<b>Date Considered</b>	09/04/2009
---------------------------	-------------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/803,653
				<b>Filing Date</b>	March 18, 2004
				<b>First Named Inventor</b>	John McCafferty, et al.
				<b>Group Art Unit</b>	1639
				<b>Examiner Name</b>	Amber D. Steele
Sheet	5	of	16	<b>Attorney Docket Number</b>	05569.0004.DVUS12

	C80	<b>Barbas, et al.</b> , "Assembly of Combinatorial Antibody Libraries on Phage Surfaces: The Gene III Site," Proc. Natl. Acad. Sci. (USA), Vol. 88, pp. 7978-7982 (1991)	
	C81	<b>Barbas, et al.</b> , "Combinatorial Immunoglobulin Libraries on the Surface of Phage (Phabs): Rapid Selection of Antigen Specific Fabs," Methods: Companion Methods Enzymol., Vol. 2, pp. 119 (1991)	
	C82	<b>Beidler, et al.</b> , "Cloning and High Level Expression of a Chimeric Antibody with Specificity for Human Carcinoembryonic Antigen," J. Immunology, Vol. 141, pp. 4053-4060 (1988)	
	C83	<b>Berborowicz and Jaroszewski</b> , "Carcinoembryonic Antigen as an Autoantigen," Immunol. Ser., Vol. 52, pp. 65-83 (1982)	
	C84	<b>Berzofsky, et al.</b> , "Antigen-Antibody Interactions and Monoclonal Antibodies," in Paul, W., Fundamental Immunology, Second Edition, Chapter 12, pp. 332 (see also, Fourth Edition, 1994 (1999) Chapter 4, p. 91)	
	C85	<b>Beste, G., et al.</b> , "Small Antibody-like Proteins with Prescribed Ligand Specificities Derived from the Lipocalin Fold," Sci. USA, Vol. 96, No. 5, pp. 1898-19903, ISSN 0027-8424 (1999) Abstract	
	C86	<b>Boerner, et al.</b> , "Production of Antigen-Specific Human Monoclonal Antibodies From in Vitro-Primed Human (Splenocytes)," J. Immunol. Vol. 147, pp. 86-95 (1991)	
	C87	<b>Breitling, et al.</b> , "A Surface Expression Vector for Antibody Screening," Gene, Vol. 104, pp. 147-153 (1991)	
	C88	<b>Buck</b> , Cell Biology, Vol. 3, pp. 179-188 (1992)	
	C89	<b>Burton, et al.</b> , "A Large Array of Human Monoclonal Antibodies to Type 1 Human Immunodeficiency Virus from Combinatorial Libraries of Asymptomatic Seropositive Individuals," Proc. Natl. Acad. Sci., Vol. 88, pp. 10134-10137 (1991)	
	C90	<b>Casali and Notkins</b> , "Probing the Human [B-cell] Repertoire with EBV: Polyreactive Antibodies and CD5+ B Lymphocytes," Ann. Rev. Immunol., Vol. 7, pp. 513-535 (1989)	
	C91	<b>Chang, et al.</b> , "Expression of Antibody Fab Domains on Bacteriophage Surfaces: Potential Use of Antibody Selection," J. Immunol., Vol. 1047, pp. 3610-3614 (1991)	
	<del>C92</del>	<del><b>Conn, P. L.</b>, "Systemic Autoimmunity," in Paul, W., Fundamental Immunology, Fourth Edition, Lippincott-Raven, p. 1608-1067.</del>	
	C93	<b>de la Cruz, et al.</b> , "Immunogenicity and Epitope Mapping of Foreign Sequences via Genetically Engineered Filamentous Phage," J. Biol. Chem., Vol. 263, No. 9, pp. 4318-4322 (1988)	
	C94	<b>Delves, P.J.</b> , "Autoimmunity," in Delves, P. and I. Roitt, The Encyclopedia of Immunology, Second Edition, Academic Press, p. 292 (1998)	

<b>Examiner Signature</b>	/Amber D. Steele/	<b>Date Considered</b>	09/04/2009
---------------------------	-------------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/803,653
				<b>Filing Date</b>	March 18, 2004
				<b>First Named Inventor</b>	John McCafferty, et al.
				<b>Group Art Unit</b>	1639
				<b>Examiner Name</b>	Amber D. Steele
Sheet	6	of	16	<b>Attorney Docket Number</b>	05569.0004.DVUS12

	C95	<b>Dighiero, et al.</b> , "Naturally Occurring Autoantibodies Against Nine Common Antigens in Human Sera," J. Immunol., Vol. 218, No. 128, pp. 2788-2792 (1982)	
	C96	<b>Dildrop, R.</b> , "A New Classification of Mouse V <sub>H</sub> sequences," Immunol. Today, Vol. 5, No. 4, pp. 85-85 (1984)	
	C97	<b>Fomsgaard, et al.</b> , "Auto-antibodies to Tumor Necrosis Factor in Healthy Humans and Patients with Inflammatory Diseases and Gram-Negative Bacterial Infections," Scand. J. Immunol., Vol. 30, pp. 219-223 (1989)	
	C98	<b>Golub, E.</b> , "The Limits of Medicine: How Science Shapes our Hope for the Cure," Times Books/Random House, p. 117-120 (1994)	
	C99	<b>Golub, E., and Green, D.</b> , "Immunology: A Synthesis," Sinauer Associates, Second Edition, p. 531 (1991)	
	C100	<b>Goodnow, et al.</b> , "Altered Immunoglobulin Expression and Functional Silencing of Self-Reactive B Lymphocytes in Transgenic Mice," Nature, Vol. 334, pp. 676-682 (1988)	
	C101	<b>Gram, et al.</b> , "In vitro Selection and Affinity Maturation of Antibodies from a Naïve Combinatorial Immunoglobulin Library," Proc. Natl. Acad. Sci USA, Vol. 89, pp. 3576-3580 (1992)	
	C102	<b>Griffiths, et al.</b> , "Human Anti-Self Antibodies with High Specificity from Phage Display Libraries, EMBO J., Vol. 12, pp. 725-734 (1993)	
	C103	<b>Griffiths, et al.</b> , "Isolation of High Affinity Human Antibodies Directly from Large Synthetic Repertoires," EMBO J., Vol. 13, pp. 3245-3260 (1994)	
	C104	<b>Guilbert, et al.</b> , "Naturally Occurring Antibodies Against Nine Common Antigens in Human Sera," J. Immunol., Vol. 128, pp. 2779-2787 (1982)	
	C105	<b>Hartley, O.</b> , "The Use of Phage Display in the Study of Receptors and Their Ligands," J. of Receptors and Signal Transduction, Vol. 22, Nos. 1-4, pp. 373-393 (2002)	
	C106	<b>Hartman and Wright</b> , "Identification of Autoantibodies Specific for the Neutrophil Adhesion Glycoproteins CD11b/CD18 in Patients with Autoimmune Disease (Neutroenia," Blood, Vol. 78, pp. 1096-1104 (1991)	
	C107	<b>Hirohata, et al.</b> , "Frequency Analysis of Human Peripheral Blood B Cells Producing IGM-Rheumatoid Factor," J. Immunol., Vol. 145, pp. 1681-1686 (1990)	
	C108	<b>Holness, et al.</b> , Journal of Cell Science, Vol. 107, pp. 2065-2070 (1994)	
	C109	<b>Hoogenboom, et al.</b> , "Building Antibodies from their Genes," Rev. Fr. Transfus. Hemobiol., Vol. 36, pp. 19-47 (1993)	
	C110	<b>Hoogenboom, et al.</b> , "Multi-Subunit Proteins on the Surface of Filamentous Phage: Methodologies for Displaying Antibody (Fab) Heavy and Light Chains," Nucl. Acids Res., Vol. 19, pp. 4133-4137 (1991)	

<b>Examiner Signature</b>	/Amber D. Steele/	<b>Date Considered</b>	09/04/2009
---------------------------	-------------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/803,653
				<b>Filing Date</b>	March 18, 2004
				<b>First Named Inventor</b>	John McCafferty, et al.
				<b>Group Art Unit</b>	1639
				<b>Examiner Name</b>	Amber D. Steele
Sheet	7	of	16	<b>Attorney Docket Number</b>	05569.0004.DVUS12

	C111	<b>Huse</b> , "Combinatorial Antibody Expression Libraries in Filamentous Phage," Chapter 5 of Antibody Engineer, Borrebaeck (ed.), W.H. Freeman and Co. N.Y. (1992)	
	C112	<b>Jacobsson, K., et al.</b> , "Shot-gun Phage Display Mapping of Two Streptococcal Cell-Surface Proteins," Microbial Research, Vol. 152, No. 2, pp. 121-128, ISSN 0944-4013 (1997) Abstract	
	C113	<b>Kabat, et al.</b> , "Sequences of Proteins of Immunological Interest," 4th ed., p. 181, (1987)	
	C114	<b>Kaushik, et al.</b> , "Comparative Analysis of Natural Antibody Specificities Among Hybridomas Originating from Spleen and Peritoneal Cavity of Adult NZB and BALB/c Mince," Scand. J. Immunol., Vol. 27, pp. 461-471 (1988)	
	C115	<b>Klein and Horejsi</b> , "Immunology" [Chapter 20, "immunological Tolerance"], Blackwell Scientific, Second Edition, p. 527 (1997)	
	C116	<b>Koga, et al.</b> , "Mouse-Human Chimeric Monoclonal Antibody to Carcinoembryonic Antigen (CEA): In Vitro and In Vivo Activities," Hybridoma, Vol. 9, pp. 43-56 (1990)	
	C117	<b>Landsteiner, K.</b> , "The Specificity of the Immune Response," quoted in Golub, E., Immunology: A Synthesis, Sinauer Associates, p. 19-25 [1991 book] (1987)	
	C118	<b>Lehninger, et al.</b> , Principles of Biochemistry, 2nd ed., Title Page, copy right page and p. G-4 only (1993)	
	C119	<b>Lobel, L.I., et al.</b> , "Filamentous Phage Displaying the Extracellular Domain of the hLH/CG Receptor Bind hCG Specifically," Endocrinology, Vol. 138, No. 3, pp. 1232-1239, ISSN: 0013-7227 (1997) Abstract	
	C120	<b>Logtenberg, et al.</b> , "Analysis of the Human Tonsil B Cell Repertoire by Somatic Hybridization: Occurrence of Both "Monospecific" and "Multispecific" (auto) Antibody-Secreting Cells," Eur. J. Immunol., Vol. 17, pp. 855-859 (1987)	
	C121	<b>Lydyard, et al.</b> , "The Antibody Repertoire of Early Human B Cells," Scand. J. Immunol., Vol. 31, pp. 33-43 (1990)	
	C122	<b>Mamula, et al.</b> , "The Specificity of Human Anti-Cytochrome c Autoantibodies that Arise in Autoimmune Disease," J. Immunol., Vol. 144, pp. 1835-1840 (1990)	
	C123	<b>Marks, et al.</b> , "Molecular Evolution of Proteins on Filamentous Phage," J. Biol. Chem., Vol. 267, p. 16007-16010 (1992)	
	C124	<b>McCafferty, J., et al.</b> , "Phage-Enzymes: Expression and Affinity Chromatography of Functional Alkaline Phosphatase on the Surface of Bacteriophage," Protein Engineering, Vol. 4, No. 8, pp. 955-961 (1991)	
	C125	<b>McHeyzer-Williams, et al.</b> , "Clonal Analysis of Autoantibody-Producing Cell Precursors in the Preimmune B Cell Repertoire," J. Immunol., Vol. 141, pp. 4118-4123 (1988)	

<b>Examiner Signature</b>	/Amber D. Steele/	<b>Date Considered</b>	09/04/2009
---------------------------	-------------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/803,653
				<b>Filing Date</b>	March 18, 2004
				<b>First Named Inventor</b>	John McCafferty, et al.
				<b>Group Art Unit</b>	1639
				<b>Examiner Name</b>	Amber D. Steele
Sheet	8	of	16	<b>Attorney Docket Number</b>	05569.0004.DVUS12

	C126	<b>Mullinax, et al.</b> , "Identification of Human Antibody Fragment Clones Specific For Tetanus Toxoid in a Bacteriophage $\lambda$ Immunoexpression Library," Proc. Natl. Acad. Sci., USA, Vol. 87, pp. 8095-8099 (1990)	
	C127	<b>Nemazee and Burk</b> , "Clonal Deletion of B Lymphocytes in a Transgenic Mouse Bearing Anti-MHC Class I Antibody Genes," Nature, Vol. 377, pp. 562-566 (1989)	
	C128	<b>Neumaier, et al.</b> , "Cloning of the Genes for T84.66, an Antibody that has a High Specificity and Affinity for Carcinoembryonic Antigen, and Expression of Chimeric Human/Mouse T84.66 Genes in Myeloma and Chinese Hamster Ovary Cells," Cancer Research, Vol. 50, pp. 2128-2134 (1990)	
	C129	<b>Nossal, G.V.J.</b> , "Cellular Mechanisms of Immune[ologic] Tolerance," Ann. Rev. Immunol., Vol. 1, pp. 33-62 (1983)	
	C130	<b>Nossal, G.V.J.</b> , "Molecular and Cellular Aspects of Immunologic Tolerance," Eur. J. Biochem., Vol. 202, pp. 729-737 (1991)	
	C131	<b>Persson, et al.</b> , "Generation of Diverse High-Affinity Human Monoclonal Antibodies by Repertoire Cloning," Proc. Natl. Acad. Sci., Vol. 88, pp. 2432-2436 (1991)	
	C132	<b>Roitt, et al.</b> , Immunology, Second Edition, 1989, Ivan Roitt, et al., Gower Publishing, New York, p. 51 (1989)	
	C133	<b>Ruf, et al.</b> , "Various Expressions of a Unique Anti-Human Thymoglobulin Antibody Repertoire in Normal State and Autoimmune Disease," Blood, Vol. 78, pp. 1096-1104 (1991)	
	C134	<b>Smith, et al.</b> , "Phage Display," Chem. Rev., Vol. 97, pp. 391-410 (1997)	
	C135	<b>Svenson, et al.</b> , "IgG Autoantibodies Against Interleukin 1 $\alpha$ in Sera of Normal Individuals," Scand. J. Immunol., Vol. 29, pp. 489-492 (1989)	
	C136	<b>Tomlinson, et al.</b> , "The Repertoire of Human Germline Vh Segments (Sequences Reveals about Fifty Groups of VH Segments) with Different Hypervariable Loops," J. Mol. Biol., Vol. 227, pp. 776-798 (1992)	
	C137	<b>Ura, et al.</b> , "Studies on Circulating Antibody Against Carcinoembryonic Antigen (CEA) and CEA-like Antigen in Cancer Patients," Cancer Letters, Vol. 25, pp. 283-295 (1985)	
	C138	<b>Waterhouse, et al.</b> , "Combinatorial Infection and in Vivo Recombination: A Strategy for Making Large Phage Antibody Repertoires," Nucl. Acids Res., Vol. 21, pp. 2265-2266 (1993)	
	C139	<b>Weidanz, J.A., et al.</b> , "Display of Functional Alphabets Single-Chain T-Cell Receptor Molecules on the Surface of Bacteriophage," J. Immunol. Methods, Vol. 221, (1-2), pp. 59-76, ISSN 0022-1759 (1998) Abstract	
	C140	<b>Wilson and Stanfield</b> , "Antibody-Antigen Interactions: New Structures and New Conformational Changes," Curr. Opin. Structural Biol., Vol. 4, pp. 857-867 (1994)	

<b>Examiner Signature</b>	/Amber D. Steele/	<b>Date Considered</b>	09/04/2009
---------------------------	-------------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/803,653
				<b>Filing Date</b>	March 18, 2004
				<b>First Named Inventor</b>	John McCafferty, et al.
				<b>Group Art Unit</b>	1639
				<b>Examiner Name</b>	Amber D. Steele
Sheet	9	of	16	<b>Attorney Docket Number</b>	05569.0004.DVUS12

	C141	Winter, et al., "Making Antibodies by Phage Display Technology," Annu. Rev. Immunol., Vol. 12, pp. 433-455 (1994)	
	C142	Promega Technical Bulletin, printed January 11, 2008, revised December 2006, pGEM-3ZF(+) Vector, 9 pages	
	C143	Promega Technical Bulletin, printed January 11, 2008, revised December 2006, pGEM-3ZF(-) Vector, 9 pages	
	C144	Stratagene Instruction Manual, printed January 11, 2008, revised 2003, pBluescript II Phagemic Vectors, 37 pages	
	C145	First Amended Complaint, Filed March 8, 2002 - Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (24 pages) (U.S. District Court, District of Columbia)(signed by John S. Skilton, Attorney for Plaintiff.)	
	C146	Cambridge Antibody Technology Limited's Answer to First Amended Complaint, Filed March 22, 2002 - Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia)(signed by Brian H. Corcoran, Attorney for Defendant).	
	C147	Il'ichev, A.A., et al., "M13 Filamentous Bacteriophage in Protein Engineering", Molekulyarnaya Biologiya, Vol. 24, No. 2, pp. 530-535, (March-April 1990).	
	C148	Iliychev, A.A., et al., "M13 Filamentous Bactiophage for Protein Engineering", Molekulyarnaya Biologiya, Vol. 24, No. 2, pp. 530-535, (March-April 1990). (In Russian with Translated Abstract)	
	C149	Deposition Transcript of David W. Clough, taken April 19, 2002 (Morphosys AG v. Cambridge Antibody Technology Limited, U.S. District Court, Northern District of Illinois, Eastern Division).	
	C150	E.I. du Pont de Nemours v. Cetus Corp., 19 USPQ2d 1174, (DC N.Cal. 1990).	
	C151	OddzOn Products Inc. v. Just Toys Inc., 43 USPQ2d 1641(CAFC 1997).	
	C152	Deposition Transcript of George P. Smith, Ph.D., taken 14 May 2002, Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia.)	
	C153	Deposition Transcript of Dr. David Chiswell, taken 29 April 2002; Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia.)	
	C154	Deposition Transcript of Dr. Gregory Paul Winter, taken April 30, 2002; Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia.)	
	C155	Vol. I - Deposition Transcript of Sean Malcolm Walton, taken 01 May 2002, Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia.)	

<b>Examiner Signature</b>	/Amber D. Steele/	<b>Date Considered</b>	09/04/2009
---------------------------	-------------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/803,653
				<b>Filing Date</b>	March 18, 2004
				<b>First Named Inventor</b>	John McCafferty, et al.
				<b>Group Art Unit</b>	1639
				<b>Examiner Name</b>	Amber D. Steele
Sheet	10	of	16	<b>Attorney Docket Number</b>	05569.0004.DVUS12

	C156	Vol. II - Deposition Transcript of Sean Malcolm Walton, taken 02 May 2002, Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia.)	
	C157	Declaration of George P. Smith, Ph.D., Under 37 C.F.R. § 1.132, executed 30 June 1995 (submitted during the prosecution of U.S. Application No. 08/322,352).	
	C158	Declaration of Brian K. Kay, Ph.D., executed 28 June 1998, (submitted during the prosecution of European Appln. No. 91913039.3)	
	C159	Abstract of George P. Smith, Grant No. 1R01GM41478-01A1, Project Start Date: July 1, 1989, Dept. of Health & Human Services.	
	C160	Smith Grant Application, entitled: "Filamentous Phage Physiology", dated November 1, 1988	
	C161	Northern Telecom Inc. v. Datapoint Corp., 15 USPQ 1321., (CAFC 1990). Letter of Dr. Smith Re: NIH grant proposals, Dated June 27, 1997	
	C162	Letter of Dr. Smith Re: NIH grant proposals dated June 27, 1997	
	C163	Barbas and Lerner "Combinatorial Immunoglobulin Libraries on the surface of phage (Phabs): rapid selection of anti-specific fabs." Methods: a companion to methods in Enzymology Vol. 2 (2): 119-124 (1991).	
	C164	Interlocutory Decision in Opposition Proceedings to the European Patent EP-B-0589877 dated April 15, 2002 (reference number SMW/CP9503921)	
	C165	Notice of Appeal to the European Patent EP-B-0589877 from Dyax Corp., filed Jun. 17, 2002	
	C166	Communication from EPO on Notice of Appeal filed by Dyax, issued October 21, 2002	
	C167	Notice of Appeal to the European Patent EP-B-0589877 from BioInvent Therapeutic AB, filed June 14, 2002	
	C168	Appeal No. T0639/02-334 from BioInvent Therapeutic AB to the European Patent EP-B-0589877, filed August 22, 2002	
	C169	Notice of Appeal to the European Patent EP-B-0589877 from MorphoSys AG filed June 20 2002 and Grounds of the Appeal filed August 22, 2002	
	C170	Notice of Appeal filed June 24, 2002 and Grounds of Appeal filed August 22, 2002 from Cambridge Antibody Technology Limited against the Decision of the Opposition Division	
	C171	Notice of Opposition to the European Patent EP-B-0589877 from BioInvent International AB, filed October 24 2002	
	<del>C172</del>	<del>Document D80 in Appeal No. T0639/02-334-1115 Freedom of Information Act (FOIA) regulations: table of contents, 5.1, 5.2, 5.3, 5.5, 5.21, 5.22, 5.24, 5.31, 5.32, 5.33, 5.34, 5.35, 5.51, 5.61 and 5.65</del>	
	<del>C173</del>	<del>Document D81 in Appeal No. T0639/02-334: Smith Declaration</del>	

<b>Examiner Signature</b>	/Amber D. Steele/	<b>Date Considered</b>	09/04/2009
---------------------------	-------------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/803,653
				<b>Filing Date</b>	March 18, 2004
				<b>First Named Inventor</b>	John McCafferty, et al.
				<b>Group Art Unit</b>	1639
				<b>Examiner Name</b>	Amber D. Steele
Sheet	11	of	16	<b>Attorney Docket Number</b>	05569.0004.DVUS12

<del>C174</del>	<del>Document D82 in Appeal No. T0639/02-334: Copy of Grant Application GM 41470 and renewal applications supplied by the DHH</del>	
C175	Document D83 in Appeal No. T0639/02-334: Letter dated 26 August 1999 from Cambridge Antibody Technology Ltd in opposition proceedings against EP 0 527 839	
C176	Document D85 in Appeal No. T0639/02-334: Proprietor's letter of 12 November 1997 and amended claims	
<del>C177</del>	<del>Document D86 in Appeal No. T0639/02-334: EP 0774 511 A1</del>	
C178	Document D87 in Appeal No. T0639/02-334: Proprietor's letter of 15 November 2000	
C179	Document D88 in Appeal No. T0639/02-334: Grounds of Appeal dated 22 August 2002 from present opponent in opposition proceedings against EP 0589 877	
<del>C180</del>	<del>Document D89 in Appeal No. T0639/02-334: OD's Written Interlocutory Decision in opposition proceedings against EP 0 589 877</del>	
C181	Document D90 in Appeal No. T0639/02-334: Marvin & Hohn (1969). Bacteriological Rev 33(2), 172-209	
C182	Document D91 in Appeal No. T0639/02-334: Better et al. (1988). Science 240, 1041-1043	
C183	Document D92 in Appeal No. T0639/02-334: Sambrook & Russell (2001). Molecular cloning: a laboratory manual 3rd Edition, Cold Spring Harbor Press; particular pages 18.115 to 18.122 "Filamentous phage display"	
C184	Notice of Opposition to the European Patent EP-B-0589877 from Crucell Holland B.V, filed October 30, 2002	
C185	Document D13: Communication of the European Office of 28 June 2001	
C186	Document D17: Vieira and Messing (1987), Methods Enzymol. 153, 3-11	
<del>C187</del>	<del>Document D27: Details of Smith Grant application and second and third year renewals thereof as provided by the DHHs in response to a Freedom to Information Act (FOIA) request</del>	
<del>C188</del>	<del>Notice of Opposition to the European Patent EP-B-0589877 from Dyax Corp.</del>	
<del>C189</del>	<del>Document D1: EPO register print-out for the patent application with file history information</del>	
<del>C190</del>	<del>Document D5: Claims filed with the divisional application</del>	
C191	Document D7: Pluckthun and Skerra, "Expression of functional antibody Fv and Fab fragments in Escherichia coli," Methods in Enzymology, Vol. 178 (1989), pages 497-515	
C192	Document D8: Hoogenboom et al., "Multi-subunit proteins on the surface of filamentous phage: methodology for displaying antibody (Fab) heavy and light chains," Nucleic Acids Research, Vol 19, No. 15 (1991), pages 4133-4137.	

<b>Examiner Signature</b>	/Amber D. Steele/	<b>Date Considered</b>	09/04/2009
---------------------------	-------------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/803,653
				<b>Filing Date</b>	March 18, 2004
				<b>First Named Inventor</b>	John McCafferty, et al.
				<b>Group Art Unit</b>	1639
				<b>Examiner Name</b>	Amber D. Steele
Sheet	12	of	16	<b>Attorney Docket Number</b>	05569.0004.DVUS12

	C193	Notice of Opposition to the European Patent EP-B-0589877 from MorphoSys, filed October 30 2002	
	<del>C194</del>	<del>Document D4: Genentech, US Patent Application 07/624,667, priority document to EP-92902109.5</del>	
	C195	Opposition to European patent EP-B-0589877, cited opposition document D2: Nelson et al. "Filamentous phage DNA cloning vectors: a noninfective mutant with a nonpolar deletion in gene III", Virology 108: 338-350 (1981)	
	C196	Opposition to European patent EP-B-0589877, cited opposition document D3: McCoy and Khorana "Introduction and characterization of amber mutations in the bacteriorhodopsin gene", J. Bio. Chem. 258: 8456-8461 (1983)	
	C197	Opposition to European patent EP-B-0589877, cited opposition document D5: Bullock et al. "XL1-blue: a high efficiency plasmid transforming recA Escherichia coli strain with beta-galactosidase selection", Bio Techniques 5: 376-378 (1987)	
	C198	Opposition to European patent EP-B-0589877, cited opposition document D6: Schnee et al. "Construction and expression of a recombinant antibody-targeted plasminogen activator", Proc. Natl. Acad. Sci. USA 84:6904-6908 (1987)	
	C199	Opposition to European patent EP-B-0589877, cited opposition document D9: De La Cruz et al. "Immunogenicity and epitope mapping of foreign sequences via genetically engineered filamentous phage", J. Bio. Chem. 263: 4318-4322 (1988)	
	C200	Opposition to European patent EP-B-0589877, cited opposition document D15: Parmley and Smith "Filamentous fusion phage cloning vectors for the study of epitopes and design of vaccines", Adv. Exp. Med. Biol. 251: 215-218 (1989)	
	C201	Opposition to European patent EP-B-0589877, cited opposition document D18: Chaudhary et al. "A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin", Nature 339: 394-397 (1989)	
	C202	Opposition to European patent EP-B-0589877, cited opposition document D23: US 517 659 "Affymax priority document", entitled "Recombinant Library Screening Methods", priority document filed 1 May 1990 for EP-A-0 527 839 (Article 54(3) EPC)	
	C203	Opposition to European patent EP-B-0589877, cited opposition document D26: Scott and Smith "Searching for peptide ligands with an epitope library", Science 249: 386-389 (1990)	
	C204	Opposition to European patent EP-B-0589877, cited opposition document D27: Devlin et al. "Random peptide libraries: a source of specific protein binding molecules", Science 249: 404-405 (1990)	

<b>Examiner Signature</b>	/Amber D. Steele/	<b>Date Considered</b>	09/04/2009
---------------------------	-------------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ADS/

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>		
				<b>Application Number</b>		10/803,653
				<b>Filing Date</b>		March 18, 2004
				<b>First Named Inventor</b>		John McCafferty, et al.
				<b>Group Art Unit</b>		1639
				<b>Examiner Name</b>		Amber D. Steele
Sheet	13	of	16	<b>Attorney Docket Number</b>		05569.0004.DVUS12

	C205	Opposition to European patent EP-B-0589877, cited opposition document D37: Markland et al. "Design, construction and function of a multicopy display vector using fusions to the major coat protein of bacteriophage M13", Gene 109: 13-19 (1991)	
	C206	Opposition to European patent EP-B-0589877, cited opposition document D38: Roberts et al. "Directed evolution of a protein: selection of potent neutrophil elastase inhibitors displayed on M13 fusion phage", Proc. Natl. Acad. Sci. USA 89: 2429-2433 (1992)	
	C207	Opposition to European patent EP-B-0589877, cited opposition document D39: Glockshuber et al. "The disulfide bonds in antibody variable domains: effects on stability, folding in vitro, and functional expression in Escherichia coli", Biochemistry 31: 1270-1279 (1992)	
	C208	Opposition to European patent EP-B-0589877, cited opposition document D41: Kay et al. "Phage display of peptides and proteins", A laboratory Manual (1996) (Cover page and Foreword enclosed)	
	C209	Opposition to European patent EP-B-0589877, cited opposition document D42: Proba et al. "A natural antibody missing a cysteine in VH: consequences for thermodynamic stability and folding", J. Mol. Biol. 265: 161-172 (1997)	
	C210	Opposition to European patent EP-B-0589877, cited opposition document D43: Proba et al. "Antibody scFv fragments without disulfide bonds made by molecular evolution", J. Mol. Biol. 275: 245-253 (1998)	
	C211	Opposition to European patent EP-B-0589877, cited opposition document D44: Letter of 18 November 1992 to EPO from Kilburn Strode in prosecution of EP-B-0 349 578	
	C212	Opposition to European patent EP-B-0589877, cited opposition document D45: Page 3 of EPO letter of 19 October 1993 addressed to Plougmann, Ole (c/o Plougmann Vingtoft A/S) in prosecution of EP-B-0 768 377	
	C213	Opposition to European patent EP-B-0589877, cited opposition document D46: Letter of 22 September 1994 to EPO from Plougmann & Vingtoft in prosecution of EP-B-0 768 377	
	C214	Opposition to European patent EP-B-0589877, cited opposition document D47: Extract from OD Decision in opposition proceedings against EP-B-0 201 184, (1995)	
	C215	Opposition to European patent EP-B-0589877, cited opposition document D48: Letter of 14 February 1996 to EPO from Hepworth, Lawrence, Bryer & Bizley in prosecution of EP-A-0 527 839, 1996	

<b>Examiner Signature</b>	/Amber D. Steele/	<b>Date Considered</b>	09/04/2009
---------------------------	-------------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/803,653
				<b>Filing Date</b>	March 18, 2004
				<b>First Named Inventor</b>	John McCafferty, et al.
				<b>Group Art Unit</b>	1639
				<b>Examiner Name</b>	Amber D. Steele
Sheet	14	of	16	<b>Attorney Docket Number</b>	05569.0004.DVUS12

	C216	Opposition to European patent EP-B-0589877, cited opposition document D49: the Boards of Appeal of the European Patent Office decision of 8 May 1996, case number T694/92 – 3.3.4	
	C217	Opposition to European patent EP-B-0589877, cited opposition document D50: Extract from opposition proceeding against EP-B-0 349 578 (1996)	
	C218	Opposition to European patent EP-B-0589877, cited opposition document D51: Extract from OD Decision in proceedings against EP-B-0 349 578 (1998)	
	C219	Opposition to European patent EP-B-0589877, cited opposition document D53: Declaration of professor sir Aaron Klug, Ph.D. with exhibits, (23 June 1998)	
	<del>C220</del>	<del>Opposition to European patent EP-B-0589877, cited opposition document D54: preprint of paper by Scott and Smith submitted to Science, date of availability to public unproven</del>	
	<del>C221</del>	<del>Opposition to European patent EP-B-0589877, cited opposition document D55: Smith grant application, date of availability to public unproven</del>	
	C222	Opposition to European patent EP-B-0589877, late filed document D56: claim for infringement of 24 September 1998, from Cambridge Antibody Technology Limited to EPO	
	C223	Opposition to European patent EP-B-0589877, late filed document D58: McConnell et al. "Constrained peptide libraries as a tool for finding mimotopes", Gene 151: 115-118 (1994).	
	C224	Opposition to European patent EP-B-0589877, late filed document D59: two chapters of "Lambda II" (eds. Hendrix et al.) Cold Spring Harbour Laboratory, Cold Spring Harbour, New York, 1983: "A Beginner's Guide to Lambda Biology" (Arber) (pp. 381-395) and "Tail Assembly and Injection" (Katsura)(pp. 331-346).	
	C225	Opposition to European patent EP-B-0589877, late filed document D60: Parmley & Smith "Filamentous fusion phage cloning vectors for the study of epitopes and design vaccines", Adv. Exp. Med. Biol. 251: 251-8 (1989). The document was not admitted to the proceedings.	
	C226	Opposition to European patent EP-B-0589877, late filed document D63: Declaration of William D. Huse, MD, Ph.D. (17 August 1999). The document was not admitted to the proceedings.	
	C227	Opposition to European patent EP-B-0589877, late filed document D66: Crissman & Smith, "Gene-III protein of filamentous phages: evidence for a carboxyl-terminal domain with a role in morphogenesis", Virology 132: 445-455 (1994).	
	C228	Opposition to European patent EP-B-0589877, late filed document D67: Declaration of Dr. Viia Valge-Archer (3 May, 2000)	
	C229	Opposition to European patent EP-B-0589877, late filed document D68: Declaration of Dr. Hiroshi Ueda (3 May, 2000)	

<b>Examiner Signature</b>	/Amber D. Steele/	<b>Date Considered</b>	09/04/2009
---------------------------	-------------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/803,653
				<b>Filing Date</b>	March 18, 2004
				<b>First Named Inventor</b>	John McCafferty, et al.
				<b>Group Art Unit</b>	1639
				<b>Examiner Name</b>	Amber D. Steele
Sheet	15	of	16	<b>Attorney Docket Number</b>	05569.0004.DVUS12

	C230	Opposition to European patent EP-B-0589877, late filed document D69: First Declaration of Dr. Rachel B. Kent (4 February, 2000). The document was objected to by patentees.	
	C231	Opposition to European patent EP-B-0589877, late filed document D71: letter of patentees filed at USPTO on 16 July 1996. The document was objected to by patentees.	
	C232	Opposition to European patent EP-B-0589877, late filed document D72: letter of patentees filed at USPTO on 6 March 1997. The document was objected to by patentees.	
	<del>C233</del>	<del>Opposition to European patent EP-B-0589877, late filed document D73: Opposition by CAT against EP-B-0-664-534. The document was objected to by patentees.</del>	
	<del>C234</del>	<del>Opposition to European patent EP-B-0589877, late filed document D74: Decision of EPPO on EP-B-0-204-484. The document was objected to by patentees.</del>	
	C235	Opposition to European patent EP-B-0589877, late filed document D75: Declaration of Prof. Andreas Plückhün (3 May, 2000). The document was objected to by patentees.	
	<del>C236</del>	<del>Opposition to European patent EP-B-0589877, late filed document D76: Notice of grant awarded to Smith grant application. The document was objected to by patentees.</del>	
	C237	Opposition to European patent EP-B-0589877, late filed document D77: Endemann and Model "Location of filamentous phage minor coat proteins in phage and in infected cells", J. Mol. Biol. 250: 496-506 (1995). The document was objected to by patentees.	
	<del>C238</del>	<del>Opposition to European patent EP-B-0589877, late filed document D79: Extract from MorphoSys website.</del>	
	C239	Opposition to European patent EP-B-0589877, late filed document D80: Written Decision dated 26 May 2000 to revoke EP-B-0436597.	
	C240	Opposition to European patent EP-B-0589877, late filed document D81: 2nd Declaration of Dr. Viia Valge-Archer (31 May, 2000).	
	C241	Complaint filed 4/23/99	
	C242	First Amended Complaint filed 5/6/99	
	C243	Defendant Cambridge Antibody Technology, Limited's Motion to Dismiss plaintiff MorPhosys Ag's Complaint filed 06/8/99	
	C244	Response of Plaintiff MorPhoSys Ag to Cambridge Antibody Technology Ltd's First Set of Interrogatories and Request for Production of Documents and Things filed 10/18/99	
	<del>C245</del>	<del>Plaintiff's Supplemental Answer to Interrogatory No. 2</del>	<del>no date or pages</del>

<b>Examiner Signature</b>	/Amber D. Steele/	<b>Date Considered</b>	09/04/2009
---------------------------	-------------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/803,653
				<b>Filing Date</b>	March 18, 2004
				<b>First Named Inventor</b>	John McCafferty, et al.
				<b>Group Art Unit</b>	1639
				<b>Examiner Name</b>	Amber D. Steele
Sheet	16	of	16	<b>Attorney Docket Number</b>	05569.0004.DVUS12

	C246	Response of Plaintiff-MorphoSys AG to Cambridge Antibody Technology Ltd.'s First Set of Interrogatories and Request for Production of Documents and Things filed 3/27/00	
	C247	Response of Plaintiff MorphoSys AG to Cambridge Antibody Technology Ltd.'s Second set of Interrogatories filed 7/3/00	
	C248	Response of MorphoSys AG to Cambridge Antibody Technology's Third Set of Interrogatories filed 8/14/00	
	C249	Declaration of Edward S. Golub, Ph.D. in Support of Morpho Sys Motion for Partial Summary Judgment of Noninfringement filed 9/1/00	
	<del>C250</del>	<del>Edward S. Golub, Ph.D. Curriculum Vitae</del>	
	C251	Expert Report of Edward S. Golub, Ph.D. dated 6/00 (with Exhibit 1) E. S. Golub Curriculum Vitae-Exhibit 2 E.S. Golub Validity Report and Exhibit 3 Declaration of E.S. Golub regarding Immunological Concepts	
	<del>C252</del>	<del>Rebuttal Expert Report of Edward S. Golub, Ph.D. no date or pages</del>	
	C253	Reply of Edward S. Golub, Ph.D. to Rebuttal Expert Reports of Edward P. Cohen, M.D. and Ronald II, Jackson, Ph.D. dated 08/01/00	
	C254	Declaration of Carlos F. Barbas III, Ph.D. in Support of MorphoSys Motion for Partial Summary Judgment of Noninfringement filed 9/1/00	
	<del>C255</del>	<del>Carlos F. Barbas III, Ph.D. Curriculum Vitae no date or pages</del>	

<b>Examiner Signature</b>	/Amber D. Steele/	<b>Date Considered</b>	09/04/2009
---------------------------	-------------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.